Pharma & Biotech - Page 5

Ipsen has announced that its Bylvay drug has failed to meet the primary endpoint in a major Phase 3 clinical trial targeting biliary atresia in young children. The French pharmaceutical company revealed

India-based active pharmaceutical ingredient makers Jagsonpal Pharmaceuticals and Tyche Industries have each received warning letters from the US Food and Drug Administration. Both companies were also placed on the FDA’s import alert

BeOne Medicines is investing $300 million into its flagship New Jersey campus to expand domestic drug manufacturing with new small molecule production capabilities. The investment targets the company’s Princeton West Innovation Campus

Roche is defending its ambitious long-term revenue forecasts for eye drug Vabysmo after the treatment fell short of analyst expectations for another quarter. Second-quarter sales of Vabysmo came in at approximately 1.04

Outside advisers to the US Food and Drug Administration have recommended relaxing restrictions on a series of popular peptide compounds sought after in wellness circles. The advisory panel delivered its recommendations following

Johnson & Johnson has reported strong phase 3 results combining its bispecific antibody Talvey with Darzalex Faspro in earlier-stage multiple myeloma patients. The data emerged from J&J’s MonumenTAL-3 phase 3 study, which

Cardinal Health (NYSE: CAH) has announced two definitive agreements totalling approximately $360 million in cash to expand its at-Home Solutions division. The company is acquiring the Diabetes Health business of AdaptHealth Corp.

ARS Pharmaceuticals (Nasdaq: SPRY) has announced a new collaboration with former NFL quarterback and 2026 Hall of Fame inductee Drew Brees to raise awareness about severe allergic reactions. The campaign centres on

GSK plc has secured its first-ever approved medicine in lung cancer after the US FDA granted approval to Jideytro (zidesamtinib) for adult patients with previously treated ROS1-positive non-small cell lung cancer. The

Healthcare’s long-promised overhaul of prior authorisation remains a work in progress, with frontline physicians reporting limited improvements despite industry pledges and new federal requirements. A new American Medical Association survey found that